Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
The immune system influences the fate of developing cancers by not only functioning as a tumour promoter that facilitates cellular transformation, promotes tumour growth and sculpts tumour cell immunogenicity, but also as an extrinsic tumour suppressor that either destroys developing tumours or restrains their expansion. Yet, clinically apparent cancers still arise in immunocompetent individuals in part as a consequence of cancer-induced immunosuppression. In many individuals, immunosuppression is mediated by cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and programmed death-1 (PD-1), two immunomodulatory receptors expressed on T cells. Monoclonal-antibody-based therapies targeting CTLA-4 and/or PD-1 (checkpoint blockade) have yielded significant clinical benefits-including durable responses--to patients with different malignancies. However, little is known about the identity of the tumour antigens that function as the targets of T cells activated by checkpoint blockade immunotherapy and whether these antigens can be used to generate vaccines that are highly tumour-specific. Here we use genomics and bioinformatics approaches to identify tumour-specific mutant proteins as a major class of T-cell rejection antigens following anti-PD-1 and/or anti-CTLA-4 therapy of mice bearing progressively growing sarcomas, and we show that therapeutic synthetic long-peptide vaccines incorporating these mutant epitopes induce tumour rejection comparably to checkpoint blockade immunotherapy. Although mutant tumour-antigen-specific T cells are present in progressively growing tumours, they are reactivated following treatment with anti-PD-1 and/or anti-CTLA-4 and display some overlapping but mostly treatment-specific transcriptional profiles, rendering them capable of mediating tumour rejection. These results reveal that tumour-specific mutant antigens are not only important targets of checkpoint blockade therapy, but they can also be used to develop personalized cancer-specific vaccines and to probe the mechanistic underpinnings of different checkpoint blockade treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The anti-tumor activity of ICB has been shown to depend on CD8+ T cell, HLA class I–dependent immune activity (34–36).”
From Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy (2018) · cites this paper as [34]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 1×
“…8,9,21,22 ; (b) whereas α CTLA-4 treatment eliminates Tregs, promotes T cell priming, and renders the host more susceptible to autoimmunity 13,22,23 ; α PD-1 promotes T cell activation acting as a rheostat of immune effector function 9,22,24,25 ; and (c) dual blockade of CTLA-4 and PD-1…”
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 2×
“…and renders the host more susceptible to autoimmunity 13,22,23 ; α PD-1 promotes T cell activation acting as a rheostat of immune effector function 9,22,24,25 ; and (c) dual blockade of CTLA-4 and PD-1 is particularly effective in promoting enhanced anti-tumour effector functions 10,22,26 .”
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationMantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399 · cited 4×
“Our findings provide some of the first experimental support for the clinical observations that (1) checkpoint blockade therapy amplifies, in some cases, preexisting anti-tumour T-cell responses(8,9,21,22); (2) whereas anti-CTLA-4 treatment eliminates regulatory T cells, promotes T-cell priming, and renders the host mo…”
InfluentialImmunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393 · cited 1×
“To increase the robustness and accuracy of our epitope predictions, we modified our method as follows: (1) mutation calls from cDNA Capture Sequencing14 were translated to corresponding protein sequences, pipelined through three MHC class I epitope-binding algorithms and a median binding affinity calculated for each p…”
Self-citationPD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378 · cited 1×
“…and renders the host more susceptible to autoimmunity 13,22,23 ; α PD-1 promotes T cell activation acting as a rheostat of immune effector function 9,22,24,25 ; and (c) dual blockade of CTLA-4 and PD-1 is particularly effective in promoting enhanced anti-tumour effector functions 10,22,26 .”
Self-citation
Cited by
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationMismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
“Due to the non-overlapping mechanism of action of anti-CTLA4 and anti-PD1 antibodies (Das et al., 2015; Gubin et al., 2014), clinical testing of the combination of these two classes of checkpoint inhibitors showed improved clinical response (up to 60”
InfluentialElements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
Metadata
- Authors
- Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., Mulder, G. E., Toebes, M., Vesely, M. D., Lam, S. S. K., Korman, A. J., Allison, J. P., Freeman, G. J., Sharpe, A. H., Pearce, E. L., Schumacher, T. N., Aebersold, R., Rammensee, H.-G., Melief, C. J. M., Mardis, E. R., Gillanders, W. E., Artyomov, M. N., & Schreiber, R. D.
- Affiliations
- Washington University in St. Louis (US)
- German Cancer Research Center (DE)
- ISA Pharmaceuticals (Netherlands) (NL)
- The Netherlands Cancer Institute (NL)
- Bristol-Myers Squibb (United States) (US)
- The University of Texas MD Anderson Cancer Center (US)
- Harvard University (US)
- University of Zurich (CH)
- Leiden University Medical Center (NL)
- Corresponding author
- Schreiber, Robert D.
- ORCID
- Gubin, Matthew M.
- Zhang, Xiuli
- Schuster, Heiko
- Ward, Jeffrey P.
- Noguchi, Takuro
- Hundal, Jasreet
- Arthur, Cora D.
- Toebes, Mireille
- Vesely, Matthew D.
- Lam, Samuel S. K.
- Korman, Alan J.
- Allison, James P.
- Freeman, Gordon J.
- Sharpe, Arlene H.
- Pearce, Erika L.
- Schumacher, Ton N.
- Aebersold, Ruedi
- Rammensee, Hans-Georg
- Melief, Cornelis J. M.
- Mardis, Elaine R.
- Gillanders, William E.
- Artyomov, Maxim N.
- Schreiber, Robert D.
- Venue
- Nature
- Published
- 2014-11-26
- Volume
- 515
- Issue
- 7528
- Pages
- 577-581
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4279952
- OpenAlex
- W2079018735
- Cited by
- 1,974
- References
- 48
- Citations by year
- 2026: 58 · 2025: 94 · 2024: 123 · 2023: 145 · 2022: 174 · 2021: 216 · 2020: 206 · 2019: 203 · 2018: 194 · 2017: 190 · 2016: 195 · 2015: 165 · 2014: 8
- FWCI
- 89.86
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion, other-oa)
- Funders
- National Institutes of Health (5u01ca141541-02)
- National Cancer Institute (P50CA101942, R01CA043059, U01-CA141541, R37CA043059, R01CA190700, P30CA016672, T32CA009547, P30CA091842)
- National Institute of Allergy and Infectious Diseases (P01AI054456, R01AI091965)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (P30AR048335)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- cancer immunotherapy, immune checkpoint blockade, anti-PD-1, anti-CTLA-4, CD8+ T cell responses, therapeutic vaccines, personalized cancer vaccines, tumor antigens, long peptide vaccine, tumor immunosuppression, tumor regression
- MeSH terms
- Animals, Antibodies, Monoclonal, Epitopes, Antigens, Neoplasm, Immunotherapy, Male, Sarcoma, Vaccines, Synthetic, CD8-Positive T-Lymphocytes, Cancer Vaccines, Mice, Cell Cycle Checkpoints
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. https://app.cochat.ai/papers/10.1038/nature13988
- The paper
- Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., Mulder, G. E., Toebes, M., Vesely, M. D., Lam, S. S. K., Korman, A. J., Allison, J. P., Freeman, G. J., Sharpe, A. H., Pearce, E. L., . . . Schreiber, R. D. (2014). Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. https://doi.org/10.1038/nature13988
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.